We are live on ! Find out more
INSY

Insys Therapeutics, Inc.
INSY

Delisted

INSY was delisted on the 18th of June, 2019.

Back to rankings

112 hedge funds and large institutions have $170M invested in Insys Therapeutics, Inc. in 2017 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 22 increasing their positions, 35 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more call options, than puts

Call options by funds: $4.87M | Put options by funds: $3.65M

3% less capital invested

Capital invested by funds: $175M → $170M (-$4.67M)

3% less funds holding

Funds holding: 116 → 112 (-4)

12% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 25

37% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 35

Holders
112
Holders Change
-4
Holders Change %
-3.45%
% of All Funds
2.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
22
Increased
22
Reduced
35
Closed
25
Calls
$4.87M
Puts
$3.65M
Net Calls
+$1.21M
Net Calls Change
+$3.24M

Top Buyers

Rank Fund Capital Flow
1
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
+$2.86M
2
EMG
ETF Managers Group
New Jersey
+$1.85M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$1.6M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$783K
5
PAM
Panagora Asset Management
Massachusetts
+$683K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$5M
2
Invesco
Invesco
Georgia
-$4.48M
3
FHAM
Folger Hill Asset Management
New York
-$3.52M
4
SCM
Schneider Capital Management
Pennsylvania
-$1.61M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$1.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
AG
76
Advisor Group
Arizona
$20K -$65 -10 -0.5%
AWA
77
Acorn Wealth Advisors
Michigan
$19K +$11.8K +1,802 New
CIBC Private Wealth Group
78
CIBC Private Wealth Group
Georgia
$19K +$13.2K +2,024 New
AIP
79
Ameritas Investment Partners
Nebraska
$17K – – –
KF
80
Krilogy Financial
Missouri
$13K – – –
Macquarie Group
81
Macquarie Group
Australia
$12K +$7.85K +1,200 New
Federated Hermes
82
Federated Hermes
Pennsylvania
$11K – – –
RFA
83
Reilly Financial Advisors
California
$10K +$6.54K +1,000 New
SWP
84
Stratos Wealth Partners
Ohio
$8K +$5.65K +863 New
AA
85
AlphaMark Advisors
Kentucky
$7K – – –
Zurich Cantonal Bank
86
Zurich Cantonal Bank
Switzerland
$7K – – –
PCM
87
Prelude Capital Management
New York
$6K -$39 -6 -0.9%
SIS
88
Sound Income Strategies
Florida
$6K +$5.24K +800 New
SIM
89
Sonora Investment Management
Arizona
$5.77K – – –
FDCDDQ
90
Federation des caisses Desjardins du Quebec
Quebec, Canada
$5.39K -$32.7K -5,000 -90%
Simplex Trading
91
Simplex Trading
Illinois
$5K +$3.54K +541 +966%
CB
92
Community Bank
New York
$4K – – –
RIA
93
RPG Investment Advisory
California
$4K – – –
IWM
94
IHT Wealth Management
Illinois
$4K +$2.39K +365 New
MAM
95
Meeder Asset Management
Ohio
$3K -$2.29K -350 -50%
BFEC
96
Benjamin F. Edwards & Company
Missouri
$3K +$1.24K +190 +127%
NSIM
97
North Star Investment Management
Illinois
$3K +$1.96K +300 New
SIAP
98
Sterling Investment Advisors (Pennsylvania)
Pennsylvania
$2K -$31.1K -4,750 -95%
WAM
99
Watermark Asset Management
California
$2K – – –
WA
100
WealthTrust-Arizona
Arizona
$2K – – –
2 3
4
5 6

INSY Hedge Fund Activity: Q4 2017 in Review

112 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q4 2017, worth a combined $170M — down 2.7% from $175M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of INSY and 22 opened new positions — a net loss of 3 holders — while 35 trimmed existing stakes and 22 added.

The largest buyer was Mirae Asset Global Investments, adding an estimated $2.86M. The largest seller was OrbiMed, cutting an estimated $5M.

  • 112 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q4 2017, down from 116 in Q3 2017.
  • Funds reported $170M of Insys Therapeutics, Inc. stock for Q4 2017, down 2.7% quarter-over-quarter.
  • 22 funds opened new Insys Therapeutics, Inc. positions in Q4 2017 and 25 closed out, a net change of -3 holders.
  • The largest Insys Therapeutics, Inc. buyer in Q4 2017 was Mirae Asset Global Investments, an estimated $2.86M added.
  • The largest Insys Therapeutics, Inc. seller in Q4 2017 was OrbiMed, an estimated $5M sold.

Based on aggregated 13F filings for Q4 2017.